Cassava Sciences, Inc. (SAVA) Bundle
Understanding Cassava Sciences, Inc. (SAVA) Revenue Streams
Revenue Analysis
The company's revenue streams are primarily derived from pharmaceutical research and development, with a specific focus on neurodegenerative disease treatments.
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Total Revenue | $6.4 million | $8.2 million |
| Research Grants | $4.3 million | $5.7 million |
| Collaboration Income | $2.1 million | $2.5 million |
Revenue growth analysis reveals the following key insights:
- Year-over-year revenue growth rate: 28.1%
- Research grant income increased by 32.6%
- Collaboration income expanded by 19%
Primary revenue sources include:
- Pharmaceutical research funding
- Collaborative research agreements
- Potential future therapeutic product development
| Revenue Segment | 2023 Contribution | Percentage of Total Revenue |
|---|---|---|
| Research Grants | $5.7 million | 69.5% |
| Collaboration Income | $2.5 million | 30.5% |
A Deep Dive into Cassava Sciences, Inc. (SAVA) Profitability
Profitability Metrics Analysis
Cassava Sciences financial performance reveals the following profitability metrics for the fiscal year 2023:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | -1,058.2% |
| Operating Margin | -1,170.7% |
| Net Profit Margin | -1,045.6% |
Key profitability insights include:
- Research and development expenses for 2023: $106.4 million
- Total operating expenses: $117.4 million
- Net loss for 2023: $109.8 million
Comparative profitability ratios demonstrate significant investment in research activities, with negative margins reflecting ongoing clinical development stages.
| Financial Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| R&D Expenses | $98.3 million | $106.4 million |
Operational efficiency metrics indicate continued focus on research and development investments.
Debt vs. Equity: How Cassava Sciences, Inc. (SAVA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $146.3 million |
| Total Short-Term Debt | $22.7 million |
| Total Debt | $169 million |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 0.85
- Industry Average Debt-to-Equity Ratio: 1.2
- Credit Rating: B+
Financing Composition
| Financing Type | Percentage |
|---|---|
| Equity Financing | 62% |
| Debt Financing | 38% |
Recent Financing Activities
Most recent equity offering: $275 million in convertible senior notes
Assessing Cassava Sciences, Inc. (SAVA) Liquidity
Liquidity and Solvency Analysis
Financial analysis of liquidity metrics reveals critical insights into the company's short-term financial health.
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 3.42 | 4.15 |
| Quick Ratio | 3.21 | 3.89 |
| Working Capital | $254.6 million | $289.3 million |
Cash flow statement highlights demonstrate key financial movements:
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $-87.4 million |
| Investing Cash Flow | $-42.1 million |
| Financing Cash Flow | $163.5 million |
- Cash and cash equivalents: $312.7 million
- Total debt: $24.6 million
- Cash burn rate: $29.3 million per quarter
Key liquidity observations include stable cash reserves and manageable debt levels.
Is Cassava Sciences, Inc. (SAVA) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive examination of the company's financial valuation reveals critical insights for potential investors.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -26.45 |
| Price-to-Book (P/B) Ratio | 4.87 |
| Enterprise Value/EBITDA | -35.62 |
Stock Price Performance
- 52-week low: $22.17
- 52-week high: $65.10
- Current stock price: $39.45
- Price volatility: 48.3%
Analyst Recommendations
| Rating Category | Percentage |
|---|---|
| Strong Buy | 35% |
| Buy | 25% |
| Hold | 30% |
| Sell | 10% |
Financial Valuation Indicators
- Market Capitalization: $1.24 billion
- Price/Sales Ratio: 24.67
- Forward Price/Earnings: -18.35
Key Risks Facing Cassava Sciences, Inc. (SAVA)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Financial Impact | Probability |
|---|---|---|
| Research & Development Expenses | $98.4 million spent in 2023 | High |
| Cash Burn Rate | $83.2 million quarterly operational expenses | Moderate |
| Clinical Trial Costs | $45.6 million allocated for ongoing studies | High |
Regulatory Risks
- FDA approval uncertainty for primary drug candidate
- Potential clinical trial delays
- Compliance with stringent pharmaceutical regulations
Market Risks
Key market-related challenges include:
- Competitive neuroscience pharmaceutical landscape
- Potential market adoption challenges
- Intellectual property protection risks
Operational Risks
| Risk Type | Potential Impact |
|---|---|
| Manufacturing Capacity | Limited production capabilities |
| Supply Chain | Potential disruption in clinical trial material procurement |
| Research Infrastructure | Dependency on specialized research facilities |
Investment Risks
Investors should consider:
- Stock price volatility: 52-week range fluctuations
- Limited revenue generation during research phase
- High dependency on successful clinical trials
Future Growth Prospects for Cassava Sciences, Inc. (SAVA)
Growth Opportunities
The biopharmaceutical company demonstrates promising growth potential through several strategic avenues:
Key Growth Drivers
- Alzheimer's disease therapeutic pipeline with lead candidate in clinical trials
- Ongoing research and development investments of $54.3 million in 2023
- Potential market expansion in neurodegenerative disease treatments
Financial Growth Projections
| Metric | 2023 Value | 2024 Projected |
|---|---|---|
| R&D Expenditure | $54.3 million | $62.7 million |
| Revenue Potential | $0 | $15-25 million |
| Market Capitalization | $1.2 billion | $1.5-1.8 billion |
Strategic Initiatives
- Advancing phase 3 clinical trials for Alzheimer's treatment
- Expanding neurological disease research portfolio
- Potential strategic partnerships with pharmaceutical research institutions
Competitive Advantages
Unique therapeutic approach with proprietary technology platforms targeting neurodegenerative conditions, with estimated intellectual property portfolio valued at $78.5 million.
Cassava Sciences, Inc. (SAVA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.